Erdotin - Healthcare Professional Area

Reference material

Click on the links below to be taken to a copy of the abstract, where available.

Copies of the full reference paper are available from Galen Ltd. Please check the boxes beside the papers you would like to request and submit your contact details below. Your local Galen representative will then deliver the relevant papers to your surgery or hospital.

Section 1 – A selection of papers demonstrating Erdotin’s anti-adhesive properties and synergistic effect with antibiotics

Braga PC et al. Effects of erdosteine and its metabolites on bacterial adhesiveness.Arzneimittel Forschung Drug Research 1999; 49(4): 344-350

Braga PC et al. Bacterial adhesiveness: effects of the SH metabolite of erdosteine (mucoactive drug) plus clarithromycin versus clarithromycin alone. Chemotherapy 2001; 47: 208-214

Dal Sasso M et al. The combination of the SH metabolite of erdosteine (a mucoactive drug) and ciprofloxacin increases the inhibition of bacterial adhesiveness achieved by ciprofloxacin alone. Drugs Exptl Clin Res 2002; XXVIII(2/3): 75-82

Marchioni CF et al. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxicillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study) Int J Clin Pharmacol Ther 1995; 33(11): 612-618

Mohanty KC et al. Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment. J Clin Research 2001; 4: 35-39.

Section 2 – A selection of papers demonstrating Erdotin’s anti-oxidant properties

Miyake K et al. The effect of erdosteine and its active metabolite on reactive oxygen species production by inflammatory cells. Inflamm res 1999; 48: 205-209

Mancini C et al. Pilot study on erdosteine activity on reduced glutathione (GSH) plasmatic levels in correlation with levels of the mother compound and main metabolite (N-thiodiglycolyl-homocysteine). 4th Eur Congress on Pharmaceutical Sciences 1998; Milano (Italy): abstract

Mitrea M et al. Reduced (GSH) and oxidized (GSSG) levels in plasma and BAL of chronic bronchitis patients treated with erdosteine or N-acetylcysteine (NAC). 6th Int Conference on BAL 1998; Corfu (Greece): abstract

Dal Negro RW et al. Antioxidant effects of erdosteine in current smokers with mild COPD (Gold Class 0-2). Eur Resp Soc Ann Congress 2006 2-6 September, Munich (Germany)

Braga PC et al. Effect of metabolite 1 of erdosteine on the release of human neutrophil elastase. Pharmacology 2006; 77: 150-154

Dal Sasso M et al. A combination of budesonide and the SH-metabolite 1 of erdosteine acts synergistically in reducing chemiluminescence during human neutrophil respiratory burst. Pharmacology 2005; 74: 127-134

Section 3 – A selection of papers demonstrating Erdotin’s mucolytic activity

Busin S et al. Erdosteine: evaluation of mucorheological and immunosecretory parameters in patients with bronchial phlogistic pathology. Med Praxis 1991; 12(4): 197-205

Marchioni CF et al. Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease. Lung 1990; 168: 285-293

Fumagalli G et al. Erdosteine: a new molecule with mucolytic activity. Clinical and instrumental evaluation in patients with acute and exacerbated chronic bronchopneumopathies. Ital J Chest Dis 1988; 42: 299-308

Dechant KL, Noble S. Erdosteine. Drugs 1996; 52(6): 875-881

Bisetti A, Mancini C. Mucolytic activity of erdosteine double blind clinical trial vs placebo. Archivio di Medicina Interna 1995; XLVII (4): 89-97

Tellings JC. Erdosteine: original secretolytic drug with mucociliary activity: a controlled clinical study vs ambroxol. Med Praxis 1991; 12(4): 183-195

Your Contact Details

Name

Surgery/Hospital

Work address

Work telephone

Email*

When you have checked the relevant papers, please click 'Submit' to send your request.

By requesting information, you are under no obligation to see a Galen representative.

*This email address will only be used to contact you regarding your request. Galen does not send unsolicited emails.

* Bisetti A, Macini C. Mucolytic activity of erdosteine double blind clinical trial vs placebo. Archivo di Medicina. Interna 1995; XLVII(4): 89-97
Marchioni CF, Polu JM, Taytard A, Hanard T, Noseda D, Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharmacol. Ther. 1995; 33(11): 612-618